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Summary 
We recently described culture conditions that allow proliferation of metastatic human breast cancer cells from 
biopsy specimens of certain patient samples. These conditions resulted in the development of an immortal- 
ized cell strain designated SUM-44PE. These same culture conditions were used to isolate a human breast 
cancer cell strain from a metastatic lymph node of a separate breast cancer patient. The SUM-16LN human 
breast cancer cells isolated from this specimen were cultured either in serum-free medium or serum-contain- 
ing medium supplemented with insulin and hydrocortisone. Unlike the SUM-44PE cells that have proliferat- 
ed in culture continuously for over two years, SUM-16LN cells proliferated in culture for approximately 200 
days and underwent 15 to 20 population doublings before undergoing cell senescence. No cells of this strain 
proliferated beyond passage 8. SUM-16LN cells were keratin-19 positive and had an aneuploid karyotype. 
These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene 
that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Despite the presence 
of high levels of tyrosine phosphorylated EGF receptor in these cells, they proliferated in serum-free, EGF- 
free medium and did not secrete detectable levels of EGF-like mitogenic growth factor. In addition, these cells 
were potently growth inhibited by all concentrations of exogenous EGF tested and by the neutralizing EGF 
receptor antibody Mab 425. These results suggest that the high level of tyrosine phosphorylated EGF receptor 
present in these cells is the direct result of receptor overexpression and not the result of the presence of a 
simulatory ligand. Thus, SUM-16LN represents a human breast cancer cell strain that exhibited genetic and 
cellular characteristics of advanced human breast cancer cells. Nevertheless, these cells exhibited a finite 
proliferative lifespan in culture, suggesting that cellular immortalization is not a phenotype expressed by all 
human breast cancer cells. 
Introduction 
Over the past 15 years many investigators have at- 
tempted to define tissue culture conditions that al- 
low the routine isolation and growth of human 
breast cancer (HBC) cells from patient biopsy spec- 
imens [1-6]. Despite these intensive efforts, pri- 
mary human breast cancer cells remain among the 
most difficult cells to isolate and grow from primary 
tissues. One aspect of the growth potential of pri- 
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mary HBC cells that may contribute to the technical 
difficulty in isolating these cells, concerns their in- 
trinsic long term growth potential. Although cellu- 
lar immortalization is a common phenotype of 
transformed rodent and human cells [7-9] and of rat 
mammary carcinoma cells [10], the question of 
whether this phenotype occurs in all human breast 
cancer cells remains open. However, Smith et al. [11] 
provided suggestive evidence that breast cancer 
cells do not have extensive proliferative potential in 
culture. 
In this report, we describe the isolation and 
growth of a human breast cancer cell strain 
(SUM-16LN) isolated from a metastatic lymph 
node of a breast cancer patient. These cells exhib- 
ited cellular and genetic characteristics of human 
breast cancer cells including an abnormal karyo- 
type, an amplified EGF receptor gene, and overex- 
pression of p53 protein. Despite these important 
cellular alterations, SUM-16LN cells exhibited a fi- 
nite proliferative lifespan in vitro. These cells were 
isolated and serially passaged seven times over ap- 
proximately 200 days. However, the cells lost prolif- 
erative potential during passage 8 and were never 
subcultureable beyond that point. Thus, human 
breast cancer cells isolated from a metastatic site 
and grown over many months in culture do not nec- 
essarily yield a truly immortalized cell line. This 
finding is consistent with the hypothesis that cellu- 
lar immortalization is not a necessary phenotype of 
human breast cancer cells. 
Materials and methods 
Isolation and culture of  SUM-16LN cells 
SUM-16LN cells were isolated by collagenase dis- 
sociation of a metastatic lymph node of a patient 
with a grade 3 infiltrating ductal carcinoma of the 
breast essentially as described previously for pri- 
mary tumor tissue [5, 6]. The isolated cells were 
seeded at 5 x 105 cells per 60 mm tissue culture dish 
and maintained in Ham's F-12 medium supple- 
mented with insulin (5 gg/ml), hydrocortisone 
(1 gg/ml), 5% fetal bovine serum, and antibiotics 
(5 %-IH medium). The cells were kept in primary 
culture for two months, and epithelial cell colonies 
were selectively removed from the stromal cell 
monolayer by incubation of the cells for 15 minutes 
at room temperature in calcium and magnesium- 
free Hanks balanced salt solution containing 
10 mM ethylene diamine tetra-acetic acid (EDTA). 
The cells isolated in this way were reseeded onto 
35 mm culture wells and maintained in secondary 
culture for an additional two months. Thereafter, 
the cells were split with a ratio of 1:3 using tryp- 
sin:EDTA. At passage 2, some of the cells were 
switched to serum-free medium supplemented with 
insulin and hydrocortisone (SF-IH medium). In the 
serum-free medium, serum is replaced with bovine 
serum albumin (1 mg/ml), ethanolamine (5 mM), 
transferrin (1 gg/ml), sodium selenite (50 ng/ml), 
and triiodothyronine (50 ng/ml). 
Cell growth assays 
To assess the growth of SUM-16LN cells in serum- 
free medium in the presence of additional exog- 
enous growth factors, cells were seeded at 105 cells 
per 35 mm culture dish in SF-IH medium and 
grown for two weeks in the presence of defined 
growth factors. After two weeks, the mean number 
of cells per dish was determined by counting isolat- 
ed nuclei with a Coulter Counter as previously de- 
scribed [12,13]. To test conditioned medium for the 
presence of EGF-like mitogenic activity, the nor- 
mal human mammary epithelial cell line MCF-10A 
was used. MCF-10A cells were seeded at 3.5 x 10 4 
cells per 35 mm culture well and grown in SF-IH 
medium in the presence or absence of 48-hour con- 
ditioned medium obtained from near confluent cul- 
tures of SUM-16LN cells. The SUM-16LN cells 
used for these experiments were grown for at least 
two passages in SF-IH medium. MCF-10A cells 
grown in SF-IH medium supplemented with 10 ng/ 
ml EGF served as positive controls. After one week 
in culture, the number of MCF-10A cells per well 
was determined by counting isolated nuclei. 
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Western blot analyses 
For preparation of membranes to be used in West- 
ern blot experiments, confluent monolayers of cells 
were scraped in 20 mM HEPES containing 20 mM 
sodium orthovanadate, 10 mM sodium pyrophos- 
phate, and I mM phenylmethyl sulfonyl fluoride 
(PMSF), dounce homogenized 50 times, and cen- 
trifuged at 800 x g for 10 minutes. The supernatant 
was then centrifuged at 100,000 x g for 30 minutes 
and the pellet resuspended in a lysis buffer consist- 
ing of 10 mM phosphate pH 7.5, 100 mM NaC1, 1% 
Triton-X 100, 0.5% sodium deoxycholate, 0.1% so- 
dium dodecyl sulfate (SDS), 5 mM sodium orthova- 
nadate, and 10 mM sodium pyrophosphate. The ly- 
sate was assayed for protein content and then de- 
fined amounts of membrane protein were added to 
individual wells and electrophoresed on a 7.5% 
SDS-polyacrylamide gel. Following electrophore- 
sis, the proteins were electroblotted onto Imobi- 
lon-P membranes (Millipore Corp., Bedford, MA), 
blocked with 2% non-fat dry milk in Tris-buffered 
saline with 1% Tween-20. Blots were probed with 
the EGF receptor antibody Ab-3 (Oncogene Sci- 
ence, Uniondale, NY) or the anti-phosphotyrosine 
antibody PY-20 (ICN, Cost a Mesa, CA). Protein 
bands were visualized by incubating blots with bio- 
tinylated secondary antibody and then with Vectas- 
tain ABC reagents (Vector Laboratories, Burlin- 
game, CA) using diaminobenzidine as a substrate. 
For immunoprecipitation experiments, 5 con- 
fluent 60 mm dishes of SUM-16LN cells were lysed 
in a buffer consisting of 10 mM Tris pH 7.6, 1% Tri- 
ton-X 100, 5 mM EDTA, 30 mM sodium pyrophos- 
phate, 50 mM sodium fluoride, 100 gM sodium or- 
thovanadate, 0.1% sodium azide, and 1 mM PMSE 
The lysate was incubated on ice for 15 minutes and 
then centrifuged at 14,000 x g for 15 minutes. The 
lysate was incubated overnight at 4°C with the 
EGF receptor antibody Ab-1 (Oncogene Science, 
Uniondale, NY) with agitation. Next, protein-A 
agarose was added to the lysate and incubated at 
room temperature for 2 hours. The beads were 
washed three times by centrifugation at 2000 x g for 
1minute. The beads were then resuspended in SDS- 
sample buffer, boiled for five minutes, centrifuged, 
and the eluates loaded onto a 7% SDS-polyacryla- 
mide gel, electrophoresed, and blotted as described 
above. 
For Western blot analysis of p53 proteins, whole 
cell lysates were prepared by scraping cells in a buff- 
er consisting of 10 mM phosphate pH 7.5,100 mM 
NaC1,1% Triton-X 100, 0.5 % sodium deoxycholate, 
and 0.1% SDS. The crude lysates were electropho- 
resed through a 10% SDS-polyacrylamide gel and 
Western blots were probed with the p53 antibody 
Ab-2 (Oncogene Science, Uniondale, NY) and pro- 
cessed as described above. Immunohistochemical 
detection of p53 in formalin-fixed, paraffin-embed- 
ded tissue sections was performed using PAb1801 
(Oncogene Science, Uniondale, NY), a murine 
monoclonal antibody specific for human p53 and 
recognizing a denaturation-resistant epitope be- 
tween amino acids 32 and 79. Pre-heated tissue sec- 
tions were deparaffinized and incubated with sup- 
pressor serum for 10 minutes. After overnight in- 
cubation with primary antibody at a 1:1000 dilution, 
sections were incubated with a 1:200 dilution of bio- 
tinylated antimouse IgG for i hour followed by suc- 
cessive incubations with 1 gg/ml streptavidin-alka- 
line phosphatase (BRL Life Technologies, Bethes- 
da, MD) and nitroblue tetrazoliurn/5-bromo-4- 
chloro-3-indolyl phosphate substrate. 
Differential polymerase chain reaction (PCR) 
DNA was isolated from SUM-16LN cells and 
MCF-10A cells using a modification of the method 
described by Kovach et al. [14]. Briefly, 10 4 m a m -  
m a r y  epithelial cells were washed three times by 
centrifugation with 5 % dextrose in water. The cell 
pellet was then resuspended in 20 gl of a buffer con- 
sisting of 10 mM Tris (pH 8.3), 50 mM KC1, 1.5 mM 
MgC12, 20 mM dithiothreitol, 1.7 gM sodium dode- 
cyl sulfate, and 10 gg proteinase K. The cells were 
incubated for i hour at 37 ° C and then incubated for 
an additional 5 minutes at 85 ° C. PCR reagents 
were then added directly to the DNA preparation. 
Differential PCR was performed using oligonu- 
cleotide primers specific for a 110 bp fragment of 
the EGF receptor gene corresponding to nucleo- 
tides 3901-4010 and a 90 bp fragment of the dopa- 
mine receptor D2 gene (DRD2) corresponding to 
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nucleotides 1464-1554. In this procedure both se- 
quences are amplified by PCR concurrently and the 
primers were homologous to the first 20 bp (sense) 
and last 20 bp (antisense) of each sequence. Re- 
agents and conditions for PCR were from the Ge- 
neAmp kit (Perkin Elmer Cetus, Norwalk, CT). 
The PCR mixture contained 10mM Tris-HC1 
(pH 8.3), 50 mM KCI, 0.2 mM each dNTP, 0.2 gM 
each oligonucleotide primer, 2.5 units Taq polym- 
erase, 1.5 mM MgCI2, and DNA obtained from 104 
mammary epithelial cells, or 100 ng of control 
DNA, in a total volume of 100 gl. Samples were 
overlaid with 80 gl mineral oil. The PCR proceeded 
through 40 cycles (1.8 min at 95 ° C, 2 min at 55 ° C, 
and 2 rain at 72 ° C) with an initial cycle of 95 ° C for 
five minutes and an end cycle of 72 ° C for 10 min- 
utes. After PCR, 10 gl of each sample was electro- 
phoresed on a 12% polyacrylamide gel and stained 
with ethidium bromide. The gels were photo- 
graphed and the band intensities were quantified 
from photographic negatives by scanning laser den- 
sitometry (Molecular Dynamics, Palo Alto, CA). 
Amplification was determined by comparing the 
ratio of EGF receptor to DRD2 band intensities be- 
tween normal mammary epithelial cells and 
SUM-16LN cells. Positive and negative control cells 
Southern blot hybridization for EGF receptor gene 
amplification. 
Results 
Isolation and growth of  SUM-16LN cells 
Recently we described culture conditions that allow 
selective isolation of human breast cancer cells 
from metastatic sites of certain patient samples [6]. 
These culture conditions were used to isolate 
SUM-16LN cells. SUM-16LN cells were plated at 
5 x 105 cells per 60 mm collagen-coated tissue cul- 
ture dish and grown in Hams F-12 medium supple- 
mented with insulin, hydrocortisone, and 5% FBS. 
Under these conditions, stromal cells grew slowly 
and formed a confluent lawn of cells that density 
arrested. Over the first 50 days in primary culture, 
epithelial cell colonies developed within the lawn of 
density arrested stromal cells. These colonies were 
then differentially isolated using 10 mM EDTA in 
calcium and magnesium Hanks balanced salt solu- 
tion. Human breast cancer cells isolated in this way 
were seeded into secondary culture and grown to 
confluence over the next 60 days. The cells were 
were obtained from matched samples of normal 
and neoplastic tissues from patients with lung ade- 
nocarcinoma that had been previously screened by 
Table 1. Culture history of SUM-16LN cells 
then subcultured with a split ratio of 1:3 approxi- 
mately once per month over the next six months. At 
the beginning of passage 2, cultures were initiated 
in serum-free medium. From passages 2 through 8, 
Passage number Days in passage Days in culture Split ratio Experiments 
Primary 51 51 - 
P1 61 112 1:3 
P2 15 127 1:3 
P3 12 139 1:3 
P3-SF 19 146 1:3 
P4 9 148 1:3 
P4-SF 15 161 1:3 
P5 20 168 1:3 
P5-SF 9 170 1:3 
P6 19 187 1:3 
P6-SF 26 196 1:3 
P7 30 217 1:3/1:1 
P7-SF 30 226 1:3/1:1 
P8 
m 
started cells in serum-free medium 
tested exogenous EGF 
performed Western blot analysis 
cells stopped growing in P7 
no cell growth 
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SUM-16LN cells were carried simultaneously in 
both the serum-containing and the serum-free 
media. The proliferative history of SUM-16LN cells 
is given in Table 1. 
Characterization of  SUM-16LN cells 
As we reported previously, SUM-16LN cells were a 
keratin-19 positive cell strain with an abnormal ka- 
ryotype [6]. The modal chromosome number was 
62 and the cells exhibited numerous marker  chro- 
mosomes. To characterize these cells further, a se- 
ries of Western blot experiments were carried out. 
SUM-16LN cells grown in the SF-IH medium for 
two to three passages were used for Western blot 
experiments. Phosphotyrosine Western blot analy- 
sis of membrane protein obtained from SUM-16LN 
cells indicated the presence of a highly tyrosine 
phosphorylated protein that migrated at approxi- 
mately 170 kDa (Fig. 1). The apparent molecular 
weight of the tyrosine phosphorylated protein was 
consistent with its identity as the E G F  receptor, and 
Western blot analysis using E G F  receptor antibod- 
ies confirmed that the two bands co-migrated on the 
gel. To confirm the identity of the p170 tyrosine 
phosphorylated protein as the E G F  receptor, im- 
munoprecipitation experiments were carried out 
using E G F  receptor antibodies. The immunopre- 
cipitates were electrophoresed and transferred to 
Immobilon-P membranes,  and the Western blots 
were probed with the phosphotyrosine antibody 
PY-20. The result of this experiment indicated 
clearly that the highly tyrosine phosphorylated p170 
is the E G F  receptor (Fig. 1). 
The results of the Western blot experiments sug- 
gested that the E G F  receptor  gene may be ampli- 
fied in these cells. In SUM-16LN cells, high levels of 
tyrosine phosphorylated E G F  receptor were de- 
tected when as little as 5 to 10 gg of membrane pro- 
tein were loaded per lane of the gel. In cells that 
express single copy levels of E G F  receptor protein, 
such as the normal human mammary epithelial cell 
line MCF-10A, 100 gg of membrane protein per 
lane is required to detect tyrosine phosphoryated 
E G F  receptor following stimulation with E G F  [15]. 
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Fig. 1. Western blot analysis of membrane protein and immu- 
noprecipitates obtained from SUM-16LN cells. Membrane pro- 
tein was obtained from near confluent cultures of SUM-16LN 
cells and defined amounts of membrane protein were loaded per 
lane, electrophoresed, blotted, and probed either with a poly- 
clonal EGF receptor antibody or an anti-phosphotyrosine anti- 
body (PY-20). Alternatively, whole cell lysates were immuno- 
precipitated with an EGF receptor antibody and Western blots 
were probed with PY-20 antibody. Lane 1,100 gg membrane pro- 
tein loaded, and blot probed with anti-EGF receptor antibody; 
Lanes 2 and 3, five or ten gg membrane protein loaded and blot 
probed with PY-20; Lane 4, EGF receptor immunoprecipitate 
loaded and blot probed with PY-20. 
gene was amplified in these cells. To confirm that 
the E G F  receptor gene was amplified, differential 
PCR analysis was carried out [16, 17]. For these ex- 
periments, primers for the human E G F  receptor 
gene and the human DRD2 gene were used. PCR 
was carried out for 40 cycles and the PCR products 
were analyzed in an ethidium bromide stained po- 
lyacrylamide gel (Fig. 2). The results of this analysis 
indicated that the ratio of the intensity of the PCR 
amplified E G F  receptor gene to the DRD2 PCR 
product was 5.2 as compared to a ratio of approxi- 
mately i for control DNA from tissue in which E G F  
receptor is not amplified. The positive control tu- 
mor sample used in this experiment also had an 
E G F  receptor to DRD2 ratio of greater than 5 and 
has been demonstrated to have a 10-fold amplifica- 
tion of E G F  receptor by Southern blot analysis [18]. 
Thus, these results are consistent with the Western 
blot experiments and indicate that E G F  receptor is 
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Fig. 2. Differential PCR analysis of SUM-16LN cells and MCF-10A cells. DNA isolated from 104 SUM-16LN cells or MCF-10A cells was 
PCR amplified using primers specific for the EGF receptor gene and the dopamine receptor gene (DRD2). PCR products were visualized 
by ethidium bromide staining of a polyacrylamide gel. The upper band represents the EGF receptor PCR product and the lower band the 
DRD2 product. The numbers below the figure represent the ratio of intensity of the upper band to the lower band. Samples 45 and 46 are 
tumor and normal cells respectively obtained from a patient with esophageal adenocarcinoma and for which Southern blotting indicated 
no amplification of the EGF receptor gene. Samples 15 and 16 refer to a similar matched pair of tissues from an esophageal adenocarcino- 
ma patient in which Southern blotting revealed a 10 to 15 fold amplification of the EGF receptor gene. 
amplified and overexpressed in SUM-16LN cells. 
Differential PCR analysis was used instead of 
Southern blot analysis because the number of cells 
available for the assay was limited. 
Since SUM-16LN cells were isolated in medium 
devoid of exogenous EGF, experiments were car- 
ried out to determine if the high level of tyrosine 
phosphorylated EGF  receptor in these cells was the 
result of the presence of low levels of an EGF-like 
ligand present in serum or the result of secretion of 
an EGF-like growth factor. To determine if EGF- 
like factors present in serum were required for 
growth of SUM-16LN, cells were tested for their 
ability to grow in serum-free medium supplement- 
ed with insulin and hydrocortisone. In the serum- 
free media used in our laboratory, serum is replaced 
with ethanolamine, transferrin, sodium selenite, tri- 
iodothyronine, and bovine serum albumin [19]. Ta- 
ble i indicates that SUM-16LN cells adapted well to 
the serum-free medium and grew over 4 passages in 
this medium. Thus, even in serum-free medium, 
SUM-16LN cells did not exhibit any requirement 
for exogenous EGF  for growth. To determine if 
SUM-16LN cells grown in serum-free medium 
would exhibit a mitogenic response to exogenous 
EGF, cells were seeded at low density in the pres- 
ence of varying concentrations of E G E  The results 
shown in Fig. 3 indicate that SUM-16LN cells were 
potently growth inhibited by exogenous EGF. Even 
concentrations as low as 0.1 ng per ml had a nega- 
tive effect on the growth of the cells. In addition, the 
neutralizing EGF  receptor antibody Mab 425 also 
inhibited growth of these cells (not shown). To de- 
termine if SUM-16LN cells were secreting an EGF- 
like growth factor, serum-free conditioned medium 
obtained from near-confluent cultures of 
SUM-16LN cells was tested for its ability to stim- 
ulate growth of MCF-10A cells in serum-free, EGF- 
free medium. We have demonstrated previously 
that MCF-10A cells do not proliferate in serum-free 
medium in the absence of EGF, and these cells are 
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Fig. 3. Growth response of SUM-16LN cells to exogenous EGE 
SUM-16LN cells that had been cultured in SF-IH medium for 
two passages were plated at 105 cells per 35 mm culture well and 
grown for two weeks in the absence or presence of varying con- 
centrations of EGF. Each point represents the mean number of 
cells per well in triplicate wells and the error bars indicate the 
range in the data. 
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Fig. 4. Analysis of SUM-16LN conditioned medium for EGF like 
mitogenic activity. MCF-10A cells were plated in 35 mm culture 
wells at 104 cells per well. The cells were then cultured for one 
week in SF-IH medium in the presence or absence of EGF or in 
SF-IH medium plus 48 hour conditioned medium obtained from 
SUM-16LN cells (50% v/v). Bars represent the mean number of 
cells in triplicate wells and error bars indicate the range in the 
data. 
biologically active EGF-l ike  growth factors [15]. 
The results shown in Fig. 4 indicate the absence of 
detectable EGF-l ike  mitogenic activity in condi- 
tioned medium of SUM-16LN cells. Taken togeth- 
er, these results suggest that the high level of phos- 
phorylated E G F  receptor  exhibited by SUM-16LN 
cells is the result of the E G F  receptor  gene amplifi- 
cation and consequent  overexpression of receptor  
protein and not the result of activation by a stim- 
ulatory ligand. 
In addition to overexpression of activated E G F  
receptor,  S U M 4 6 L N  cells also overexpressed p53 
protein. Western blot analysis carried out with ly- 
sates obtained with SUM-16LN cells indicated the 
presence of p53 protein levels similar to that ob- 
served with T-47D cells that are known to have a 
mutant  p53 gene (Fig. 5a). Immunohis tochemical  
analysis of the biopsy specimen that yielded this cell 
strain confirmed this result and indicated positive 
nuclear staining for p53 in the breast  cancer cells in 
both the pr imary tumor  specimen and the metastat-  
ic lymph node (Fig. 5b and 5c). The nuclear staining 
pat tern of p53 protein is consistent with the pres- 
ence of a p53 mutat ion in these cells. This finding 
also provides further evidence that the cell strain 
isolated from this specimen is representative of the 
breast cancer cells of this patient. 
Loss of  proliferative potential of  SUM-16LN cells 
Table i indicates that SUM-16LN cells proliferated 
continuously in both the serum-containing and se- 
rum-free media for approximately 200 days before 
losing growth potential. The cells then expressed a 
classic pat tern of cellular senescence. Upon  sub- 
culture to passage 8 the cells abruptly s topped pro- 
liferating and underwent morphological  changes 
consistent with cellular senescence. Reinitiating 
SUM-16LN cultures by thawing frozen ampoules of 
cells prepared  at earlier passage levels or by thaw- 
ing ampoules of the original cell preparat ion failed 
to generate cells that would proliferate beyond pas- 
sage 8. In addition, many unsuccessful at tempts 
were made to modify the culture conditions for 
SUM-16LN cells at earlier passage levels by altering 
the substratum on which they were grown and by 
testing their responsiveness to several hormones  
and growth factors. Thus, these results indicate that 
SUM-16LN represents a true human breast  cancer 
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Fig. 5. p53 overexpression in SUM-16LN cells. Panel A, Western blot analysis of cell lysates obtained from T47-D human breast cancer 
cells (lane 1), SUM-44PE human breast cancer cells (lane 2), and SUM-16LN cells (lane 3). Panels B and C, Immunohistochemical 
analysis of the primary tumor specimen from which the SUM-16LN strain was derived, Note the absence of p53 nuclear staining in an area 
of the tumor consisting of intraductal carcinoma (panel B, 20 x) and intense nuclear p53 staining of the breast cancer cells in the invasive 
component of the tumor (panel C, 40 x). 
cell strain that expressed a finite proliferative life- 
span in vitro. 
Discussion 
It is often difficult to distinguish in absolute terms 
the difference between a finite proliferative life- 
span of cells measured in vitro and the loss of 
growth potential that results from deficiencies in 
tissue culture conditions. With regard to human 
breast cancer cells, this question has been particu- 
larly difficult to address due to the inherent difficul- 
ty in the isolation and growth of human breast can- 
cer cells from primary tissues. Clearly, some human 
breast cancer cells are immortalized as a small per- 
centage of human breast cancer specimens yield im- 
mortalized cell lines. The frequency with which hu- 
man breast cancer cell lines have been developed 
has increased in recent years as tissue culture meth- 
ods have improved [3, 4,19]. However,  the vast ma- 
jority of human breast cancer cells obtained from 
primary or metastatic sites do not yield permanent  
cell lines. In 1987 Smith et al. [11] suggested that the 
proliferative lifespan of some human breast cancer 
cells is indeed quite limited. In those studies, serial 
pleural effusion specimens were obtained from the 
same patient over a 2 year period. Cells obtained 
from the first two specimens did not proliferate in 
culture but cells from the third sample grew and 
yielded a long-term breast cancer cell line. 
In these report, we extend the observations made 
earlier by Smith and co-workers [11]. We have de- 
veloped culture methods that support establish- 
ment and proliferation of metastatic human breast 
cancer cells from some patients. These methods re- 
sulted in the isolation and growth of the human 
breast cancer cell line SUM-44PE [6] and a second 
cell line designated SUM-52PE that is currently be- 
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ing further characterized. These same culture con- 
ditions were used to isolate and grow the cell strain 
SUM-16LN described here. Interestingly, the 
course of cell growth of SUM-16LN was very similar 
to that expressed by the SUM-44PE cells in early 
passages. However, whereas SUM-44PE cells con- 
tinued to express proliferative potential and are 
growing nearly two years later, SUM-16LN cells 
ceased to proliferate and senesced at passage 8, af- 
ter approximately 200 days in culture. Although it is 
difficult to determine precisely, we estimate that 
SUM-16LN cells underwent 15 to 20 population 
doublings before losing growth potential. The fact 
that these cells were isolated and cultured for many 
months before losing proliferative potential under 
the same culture conditions that have supported 
continuous growth of two other cell lines, suggests 
that SUM-16LN were not immortal but rather had a 
finite proliferative capacity. However, one can nev- 
er completely rule out the possibility that deficien- 
cies in culture conditions contributed to the demise 
of SUM-16LN cells in ways that did not affect other 
breast cancer cell lines. 
SUM-16LN cells exhibited several interesting ge- 
netic alterations. First, these cells were aneuploid 
with a modal chromosome number of 62 and con- 
tained several marker chromosomes [6]. In addi- 
tion, these cells overexpressed p53 protein and con- 
tained an amplified EGF receptor gene that result- 
ed in high level expression of tyrosine phosphory- 
lated EGF receptor even when grown over several 
passages in serum-free, EGF-free medium, and 
EGF-like mitogenic activity was not detected in 
conditioned medium from these cells. These results 
suggest that overexpression of the receptor protein 
itself results in high levels of tyrosine phosphorylat- 
ed receptor in the absence of ligand. The most re- 
cent models of activation of EGF receptor tyrosine 
kinase have proposed that EGF receptors exist in a 
dynamic equilibrium between monomeric and di- 
meric states and that the presence of ligand shifts 
the equilibrium toward the dimeric (kinase active) 
state [21, 22]. EGF receptor dimers then undergo 
tyrosine phosphorylation by an intermolecular 
mechanism. A corollary of this hypothesis is that all 
cells have low levels of EGF receptor dimers in the 
absence of ligand but the levels of kinase active re- 
ceptors are insufficient to yield a mitogenic signal. 
If this is correct, then amplification of the receptor 
may itself result in the presence of sufficient num- 
bers of receptor dimers per cell to yield active mito- 
genic signaling. Indeed, high levels of tyrosine 
phosphorylated receptors are a common observa- 
tion in cells that have amplification of EGF recep- 
tor or erbB-2 receptor genes [23, 24]. 
Although the very high levels of tyrosine phos- 
phorylated EGF receptors in these cells are incon- 
sistent with the presence of very low levels of EGF- 
like ligand, one cannot completely rule out the pos- 
sible contribution of a non-secreted growth factor 
such as incompletely processed TGF-c~ that could 
be acting via a juxtacrine mechanism. Unfortunate- 
ly, the senescence of the SUM-16LN cell strain oc- 
curred before sufficient cells could be obtained to 
carry out a thorough Northern analysis to address 
this question. 
In summary, SUM-16LN cells are a human breast 
cancer cell strain isolated from a metastatic lymph 
node of a patient with grade 3 infiltrating ductal car- 
cinoma of the breast. These cells, which have an ab- 
normal karyotype, and overexpress both p53 pro- 
tein and EGF receptor protein, have a finite prolif- 
erative lifespan in vitro and senesced after 15 to 20 
population doublings. These results are consistent 
with the hypothesis that cellular immortalization is 
not a characteristic of all human breast cancer cells. 
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